Allogeneic platform for regenerative cell therapy by non-viral gene knockdown

The goal of this project is develop a platform for engineering cells from non-autologous sources for cell therapy. We will use a transposon-based non-viral gene editing system that is safer, less expensive, and bypasses regulatory burdens compared to more common similar methods. This allogeneic platform will provide an off-the-shelf source for cell therapy that can be mass-manufactured to higher and more consistent release criteria than autologous sources.